Orbimed Advisors LLC Has $31.48 Million Holdings in Aerie Pharmaceuticals Inc (AERI)

Orbimed Advisors LLC cut its position in shares of Aerie Pharmaceuticals Inc (NASDAQ:AERI) by 28.5% during the fourth quarter, HoldingsChannel.com reports. The firm owned 872,100 shares of the company’s stock after selling 347,730 shares during the quarter. Orbimed Advisors LLC’s holdings in Aerie Pharmaceuticals were worth $31,483,000 at the end of the most recent quarter.

A number of other hedge funds have also recently modified their holdings of the business. Bank of Montreal Can raised its stake in Aerie Pharmaceuticals by 40.2% during the fourth quarter. Bank of Montreal Can now owns 1,060 shares of the company’s stock worth $38,000 after purchasing an additional 304 shares during the period. Zurcher Kantonalbank Zurich Cantonalbank raised its stake in Aerie Pharmaceuticals by 23.0% during the fourth quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 2,753 shares of the company’s stock worth $99,000 after purchasing an additional 515 shares during the period. State Board of Administration of Florida Retirement System raised its stake in Aerie Pharmaceuticals by 3.6% during the fourth quarter. State Board of Administration of Florida Retirement System now owns 19,031 shares of the company’s stock worth $687,000 after purchasing an additional 660 shares during the period. Chartwell Investment Partners LLC raised its stake in Aerie Pharmaceuticals by 3.2% during the fourth quarter. Chartwell Investment Partners LLC now owns 23,735 shares of the company’s stock worth $857,000 after purchasing an additional 734 shares during the period. Finally, Teachers Advisors LLC raised its stake in Aerie Pharmaceuticals by 1.1% during the third quarter. Teachers Advisors LLC now owns 70,937 shares of the company’s stock worth $4,366,000 after purchasing an additional 772 shares during the period.

AERI has been the topic of a number of analyst reports. ValuEngine downgraded shares of Aerie Pharmaceuticals from a “buy” rating to a “hold” rating in a research note on Tuesday, November 27th. BidaskClub raised shares of Aerie Pharmaceuticals from a “sell” rating to a “hold” rating in a research note on Thursday, January 31st. Mizuho reaffirmed a “buy” rating and set a $77.00 target price on shares of Aerie Pharmaceuticals in a research note on Tuesday, November 27th. Zacks Investment Research downgraded shares of Aerie Pharmaceuticals from a “hold” rating to a “sell” rating in a research note on Tuesday, January 15th. Finally, Canaccord Genuity set a $65.00 target price on shares of Aerie Pharmaceuticals and gave the stock a “buy” rating in a research note on Thursday, December 20th. Two investment analysts have rated the stock with a sell rating, two have issued a hold rating and nine have issued a buy rating to the company. The stock has a consensus rating of “Buy” and a consensus target price of $76.64.

In other news, insider Casey C. Kopczynski sold 11,000 shares of the business’s stock in a transaction that occurred on Friday, February 1st. The shares were sold at an average price of $46.17, for a total value of $507,870.00. Following the sale, the insider now directly owns 97,243 shares of the company’s stock, valued at approximately $4,489,709.31. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. 10.53% of the stock is currently owned by insiders.

Aerie Pharmaceuticals stock opened at $47.09 on Tuesday. The company has a market capitalization of $2.14 billion, a PE ratio of -10.13 and a beta of 0.97. Aerie Pharmaceuticals Inc has a 1 year low of $32.18 and a 1 year high of $74.75.

ILLEGAL ACTIVITY NOTICE: This piece of content was originally published by WKRB News and is owned by of WKRB News. If you are viewing this piece of content on another publication, it was copied illegally and republished in violation of United States & international copyright & trademark legislation. The legal version of this piece of content can be viewed at https://www.wkrb13.com/2019/03/19/orbimed-advisors-llc-has-31-48-million-holdings-in-aerie-pharmaceuticals-inc-aeri.html.

About Aerie Pharmaceuticals

Aerie Pharmaceuticals, Inc, an ophthalmic pharmaceutical company, focuses on the discovery, development, and commercialization of first-in-class therapies for the treatment of glaucoma and other eye diseases. Its lead product is Rhopressa, a once-daily eye drop to reduce elevated intraocular pressure (IOP) in patients with glaucoma or ocular hypertension.

Further Reading: Do investors pay a separate front-end load every time they buy additional shares?

Want to see what other hedge funds are holding AERI? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Aerie Pharmaceuticals Inc (NASDAQ:AERI).

Institutional Ownership by Quarter for Aerie Pharmaceuticals (NASDAQ:AERI)

Receive News & Ratings for Aerie Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aerie Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.